0001544227
2024-01-01
2024-12-31
0001544227
2024-06-28
0001544227
2025-04-25
0001544227
us-gaap:CommonStockMember
2024-01-01
2024-12-31
0001544227
tpst:SeriesAJuniorParticipatingPreferredPurchaseRightsMember
2024-01-01
2024-12-31
iso4217:USD
shares
0001544227
FY
true
10-K/A
true
2024-12-31
--12-31
2024
false
001-35890
Tempest Therapeutics, Inc.
DE
45-1472564
2000 Sierra Point Parkway,
Suite 400
Brisbane
CA
94005
415
798-8589
Common Stock, $0.001 par value
TPST
NASDAQ
Series A Junior Participating Preferred Purchase Rights
NASDAQ
No
No
Yes
Yes
Non-accelerated Filer
true
false
false
false
true
53600000
3655015
Ernst & Young LLP
Chicago, Illinois
42
false
true
<div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman";"><div style="font-weight:bold;display:inline;">Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we grant stock options to our employees, including our named executive officers. Historically, we have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">granted new-hire option</div> awards on or soon after a new hire’s employment start date and annual refresh employee option grants in the first quarter of each fiscal year, which refresh grants are typically approved at the regularly scheduled meeting of the Compensation Committee occurring in such quarter. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Also, non-employee directors</div> receive automatic grants of initial and annual stock option awards, on the date of each annual meeting of stockholders, pursuant to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">the non-employee director</div> compensation policy, as further described under the heading, “<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Director Compensation— <div style="white-space:nowrap;display:inline;">Non-Employee</div> Director Compensation Program</div></div>” below. We do not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features. The Compensation Committee considers whether there is any material nonpublic information (“MNPI”) about the Company when determining the timing of stock option grants and does not seek to time the award of stock options in relation to our public disclosure of MNPI. We have not timed the release of MNPI for the purpose of affecting the value of executive compensation. </div>
false
The Compensation Committee considers whether there is any material nonpublic information (“MNPI”) about the Company when determining the timing of stock option grants and does not seek to time the award of stock options in relation to our public disclosure of MNPI. We have not timed the release of MNPI for the purpose of affecting the value of executive compensation.
true
false